Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.

PHASE3CompletedINTERVENTIONAL
Enrollment

228

Participants

Timeline

Start Date

February 3, 2020

Primary Completion Date

August 11, 2021

Study Completion Date

September 16, 2021

Conditions
Atopic Dermatitis
Interventions
BIOLOGICAL

Lebrikizumab

Subcutaneous injection

OTHER

Placebo

Subcutaneous injection

OTHER

Topical Corticosteroid

Topical Corticosteroid

Trial Locations (63)

10075

Sadick Research Group, New York

13055

Praxis für Ganzheitliche Dermatologie im Ärztehaus, Berlin

20016

Foxhall Dermatology, Washington D.C.

20537

TFS Trial Form Support GmbH, Hamburg

20850

Dermatology and Skin Cancer Specialists, Rockville

21614

Elbe Klinikum Buxtehude, Buxtehude

28277

OnSite Clinical Solutions, Charlotte

28405

Wilmington Dermatology Center, Wilmington

29407

Clinical Research Center of the Carolinas, Charleston

30328

Advanced Medical Research, Sandy Springs

32606

University of Florida - Gainesville, Gainesville

33012

Direct Helpers Medical Center, Hialeah

33016

The Community Research of South Florida, Hialeah

33063

GSI Clinical Research, LLC, Margate

33100

Alergo-Med Specjalistyczna Przychodnia Lekarska Sp Z O.O., Tarnów

33135

Vitae Research Center, LLC, Miami

33143

Well Pharma Medical Research Corp., Miami

33765

St. Francis Medical Institute, Clearwater

46168

The Indiana Clinical Trials Center, Plainfield

48103

Fivenson Dermatology, Ann Arbor

48346

Clarkston Skin Research, Clarkston

60590

Klinikum der Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt am Main

64506

MediSearch Clinical Trials, Saint Joseph

75230

Dermatology Treatment and Research Center, Dallas

76011

Arlington Research Center, Inc, Arlington

85255

Investigate MD, Scottsdale

90025

California Allergy and Asthma Medical Group + Research Center, Los Angeles

90033

Keck School of Medicine University of Southern California, Los Angeles

90045

Dermatology Research Associates, Los Angeles

90057

LA Universal Research Center, INC, Los Angeles

90211

Wallace Medical Group, Inc., Beverly Hills

92119

ACRC Studies, San Diego

92123

University Clinical Trials, Inc., San Diego

92701

Southern California Dermatology, Inc., Santa Ana

92708

First OC Dermatology, Fountain Valley

92801

Orange County Research Institute, Anaheim

93309

Bakersfield Dermatology and Skin Cancer Medical Group, Bakersfield

94538

Center For Dermatology Clinical Research, Inc., Fremont

97210

Oregon Dermatology and Research Center, Portland

97223

Oregon Medical Research Center, Portland

97239

OHSU Center for Health and Healing, Portland

97504

Clinical Research Institute, Medford

33613-1244

ForCare Clinical Research, Tampa

01915

ActivMed Practices and Research, Beverly

02169

Beacon Clinical Research LLC, Quincy

03801

ALLCUTIS Research, Portsmouth

08520

Psoriasis Treatment Center of Central New Jersey, East Windsor

02919

Clinical Partners, LLC, Johnston

T4N 6V7

CARe Clinic, Red Deer

V3R 6A7

Dr. Chih-ho Hong Medical Inc., Surrey

V3V 0C6

Enverus Medical Research, Surrey

R3M 3Z4

Wiseman Dermatology Research Inc., Winnipeg

K9J 5K2

SKiN Centre for Dermatology, Peterborough

H3H1V4

International Dermatology Research, Montreal

01307

Technische Universitaet Dresden - Universitaetsklinikum Carl Gustav Carus - Klinik und Poliklinik fuer, Dresden

51-318

DermMEDICA Sp. z o.o., Wroclaw

35-055

Kliniczny Szpital Wojewodzki nr. 1 Klinika Dermatologii, Rzeszów

80-219

COPERNICUS Podmiot Leczniczy sp. z o.o., Gdansk

42-624

Labderm s.c., Ossy

80-405

Clinica Vitae Sp. z o.o., Gdansk

01-142

Clinical Research Group Sp. z o.o., Warsaw

02-507

Centralny Szpital Kliniczny MSWiA, Warsaw

25-155

Gabinet Dermatlogiczny. Beata Krecisz, Kielce

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Dermira, Inc.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT04250337 - Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis. | Biotech Hunter | Biotech Hunter